Ryan Scott

Dr. Regina Hampton shares case studies from her own practice, illustrating how genomic insights have improved patient outcomes in those with breast cancer.

SpaceOAR Hydrogel reduced the risk of bowel disorders, the need for colonoscopy and rectal resection following radiation therapy in prostate cancer.

Dr. Debu Tripathy explains how ctDNA is used to in breast cancer detection and how it can also indicate the presence of MRD.

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 gozetotide in PSMA-PET scans.

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the potential for improved outcomes.

The FDA has granted approval to an act of compassionate use treatment with the anti-cancer drug Namodenoson for a patient with pancreatic cancer.

Dr. Regina Hampton highlighted unmet needs in black women with breast cancer and details how genomic information can drive effective treatment options.

The first patient has been dosed in a phase 2b trial evaluating the first-in-class agent Halneuron for those with neuropathic pain following chemotherapy.

Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type of non-Hodgkin's lymphoma.

Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ablative options.

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, highlighting recent advancements.

Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by conventional imaging.

Blue light cystoscopy had a statistically significant reduction in risk of recurrence versus white light cystoscopy in high-risk bladder cancer.

The phase 2 TEDOPaM trial evaluating patients with advanced or metastatic pancreatic ductal adenocarcinoma met its primary end point.

The first patient has been enrolled in the phase 3 PROSTATE-IQ trial being conducted in men with prostate cancer recurrence following a prostatectomy.

Artificial intelligence aids in polyp detection, enhancing colonoscopy effectiveness and reducing the risk of colorectal cancer progression in patients.

Treatment with thermal ablation was noninferior to surgical resection in small-size colorectal liver metastases, according to the COLLISION trial.

Dr. Park shares the three biggest takeaways, in his opinion, to have come out of the ASCO GU Symposium, highlighting studies across kidney, bladder and prostate cancers.

Replacing transplant and chemo with CI-based therapy and ISRT maintains survival, reduces side effects in younger patients with classic Hodgkin lymphoma.

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer.

Treatment with the CAR T-cell therapy cema-cel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphoma.

Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.

Fractionated reirradiation is safe and feasible, suggesting higher reirradiation dose may be feasible in patients with recurrent high-grade glioma.

Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer.

Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus chemo alone in resectable NSCLC.

Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have progressed after CAR-T therapy.

Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety and antileukemic activity.

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.

The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or refractory multiple myeloma.